- Home
- SPHL vs TOVX Comparison
SPHL vs TOVX Comparison
Compare SPHL & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPHL
- TOVX
- Stock Information
- Founded
- SPHL 2002
- TOVX 2001
- Country
- SPHL Singapore
- TOVX United States
- Employees
- SPHL N/A
- TOVX N/A
- Industry
- SPHL Homebuilding
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- SPHL Consumer Discretionary
- TOVX Health Care
- Exchange
- SPHL Nasdaq
- TOVX Nasdaq
- Market Cap
- SPHL 4.9M
- TOVX 4.5M
- IPO Year
- SPHL 2024
- TOVX 2006
- Fundamental
- Price
- SPHL $0.37
- TOVX $0.40
- Analyst Decision
- SPHL
- TOVX Hold
- Analyst Count
- SPHL 0
- TOVX 1
- Target Price
- SPHL N/A
- TOVX N/A
- AVG Volume (30 Days)
- SPHL 48.9K
- TOVX 1.1M
- Earning Date
- SPHL 01-01-0001
- TOVX 08-11-2025
- Dividend Yield
- SPHL N/A
- TOVX N/A
- EPS Growth
- SPHL N/A
- TOVX N/A
- EPS
- SPHL N/A
- TOVX N/A
- Revenue
- SPHL $6,456,601.00
- TOVX N/A
- Revenue This Year
- SPHL N/A
- TOVX N/A
- Revenue Next Year
- SPHL N/A
- TOVX N/A
- P/E Ratio
- SPHL N/A
- TOVX N/A
- Revenue Growth
- SPHL N/A
- TOVX N/A
- 52 Week Low
- SPHL $0.35
- TOVX $0.37
- 52 Week High
- SPHL $7.80
- TOVX $4.97
- Technical
- Relative Strength Index (RSI)
- SPHL 35.76
- TOVX 41.52
- Support Level
- SPHL $0.39
- TOVX $0.39
- Resistance Level
- SPHL $0.48
- TOVX $0.45
- Average True Range (ATR)
- SPHL 0.06
- TOVX 0.03
- MACD
- SPHL -0.01
- TOVX -0.00
- Stochastic Oscillator
- SPHL 2.25
- TOVX 15.80
About SPHL Springview Holdings Ltd Class A Ordinary Shares
Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.